Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | VNN1 | O95497 | 13/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22151099 | 0.89 | PTGS1 (0.53) | PTGS1KCNH2VNN1 | |
| SCHEMBL22151097 | 0.89 | PTGS1 (0.53) | PTGS1KCNH2VNN1 | |
| SCHEMBL22151100 | 0.89 | PTGS1 (0.53) | PTGS1KCNH2VNN1 | |
| SCHEMBL22170810 | 0.85 | PTGS1 (0.56) | PTGS1KCNH2VNN1 | |
| SCHEMBL25759733 | 0.85 | PTGS1 (0.56) | PTGS1KCNH2VNN1 | |
| SCHEMBL7049047 | 0.80 | PTGS1 (0.62) | PTGS1KCNH2VNN1 | |
| SCHEMBL22197940 | 0.79 | PTGS1 (0.57) | PTGS1KCNH2VNN1 | |
| SCHEMBL24295732 | 0.79 | PTGS1 (0.43) | PTGS1KCNH2VNN1 | |
| SCHEMBL24295774 | 0.79 | PTGS1 (0.43) | PTGS1KCNH2VNN1 | |
| SCHEMBL24296115 | 0.79 | VNN1 (0.51) | PTGS1KCNH2VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834391-B2 | Pantothenamide analogues | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2023-12-05 | — | — | US | disclosed |
| US-20230159437-A1 | PANTOTHENAMIDE ANALOGUES | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834391-B2 | Pantothenamide analogues | NAMPT, VKORC1, NME4 | PTGS1 991/4885KCNH2 3921/4885VNN1 5/4885 |
| US-20230159437-A1 | PANTOTHENAMIDE ANALOGUES | NAMPT, VKORC1, NME4 | PTGS1 991/4885KCNH2 3921/4885VNN1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.